Background：Tesidolumab, as known as LFG-316, is a human immunoglobulin G1 IgG1 monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity. The drug has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others. In addition, it has reached Phase II clinical trial as a potential therapy for the ocular conditions, geographic atrophy, wet age-related macular degeneration and non-infectious uveitis.
